The simultaneous inhibition of SHIP1 and -2 using pan-SHIP1/2 inhibitors may offer a unique opportunity to enhance the basal homeostatic function of microglia that could be leveraged for therapeutic purposes in AD and potentially other neurodegenerative conditions that are also characterized by similar perturbations in microglia function. Here, INPP5D is linked to Alzheimer disease.